{
    "clinical_study": {
        "@rank": "9973", 
        "arm_group": {
            "arm_group_label": "Patients with PAOD or aneurysms", 
            "description": "Patients\nin Fontaine class > IIa,\nin need of aneurysm repair,\nwith defined cardiovascular risk factors or\ngraft infections.\nSurgical reconstruction with defined Silver Graft vascular prosthesis."
        }, 
        "brief_summary": {
            "textblock": "This web based e-Registry will be international, multi-center and prospective. Silver Graft\n      e-Registry to assess the long term clinical benefit of Silver Graft in an unselected patient\n      population"
        }, 
        "brief_title": "Silver Graft All Comers Registry", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Aneurysm", 
            "Graft Failure", 
            "Graft Infection"
        ], 
        "condition_browse": {
            "mesh_term": "Aneurysm"
        }, 
        "detailed_description": {
            "textblock": "To assess the long term clinical benefit of Silver Graft in an unselected patient population\n      with Peripheral Artery Occlusive Disease (PAOD) fulfilling one of the the following\n      criteria:\n\n        1. Any suitable patient in need of an infrarenal vascular reconstruction with Fontaine\n           class IIb or indicated vascular reconstruction aneurysm repair.\n\n           or\n\n        2. Any suitable patient with an increased risk for early graft failure except those\n           mentioned under (3). These may include\n\n             -  diabetics\n\n             -  Fontaine class> IIb\n\n             -  patients of advanced age (\u226575 y)\n\n             -  patients with renal insufficiency (creatinine \u2265 1.50 mg/dl or \u2265130 \u00b5mol/l)\n\n             -  patients with COPD or documented coronary artery disease (prior PCI, prior CABG,\n                documented myocardial ischemia)\n\n             -  patients with major amputation\n\n             -  immunosuppressed patients\n\n             -  patients with autoimmune disease, malignancy\n\n           or\n\n        3. Any suitable patient with graft infection or present infection in the anatomical\n           position of indicated vascular reconstruction."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Any suitable patient in need of an infrarenal vascular reconstruction with Fontaine\n             class IIb or indicated vascular reconstruction aneurysm repair.\n\n          2. Any suitable patient with an increased risk for early graft failure except those\n             mentioned under (3). These may include\n\n               -  diabetics\n\n               -  Fontaine class> IIb\n\n               -  patients of advanced age (\u226575 y)\n\n               -  patients with renal insufficiency (creatinine \u2265 1.50 mg/dl or \u2265130 \u00b5mol/l)\n\n               -  patients with COPD or documented coronary artery disease (prior PCI, prior CABG,\n                  documented myocardial ischemia)\n\n               -  patients with major amputation\n\n               -  immunosuppressed patients\n\n               -  patients with autoimmune disease, malignancy\n\n          3. Any suitable patient with graft infection or present infection in the anatomical\n             position of indicated vascular reconstruction.\n\n        Exclusion Criteria:\n\n          -  Any patient with common contraindications for vascular surgery may not be included in\n             this registry.\n\n          -  Any patient with an estimated life expectancy less than the first follow-up period,\n             i.e. 12 months is excluded from data entry.\n\n          -  Any patient with a known and documented allergy to silver or silver ions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with PAOD Fontaine classification > IIa Patients in need of aneurysm repair\n        Patients in need of revisions, i.e. graft infections"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970605", 
            "org_study_id": "AAG-O-H-1310"
        }, 
        "intervention": {
            "arm_group_label": "Patients with PAOD or aneurysms", 
            "description": "In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.\nCommon practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.\nDue to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible.", 
            "intervention_name": "Surgical reconstruction", 
            "intervention_type": "Procedure", 
            "other_name": [
                "Vascular reconstruction", 
                "Vascular prosthesis", 
                "Silver Graft"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "contact": {
                "email": "joerg.tautenhahn@klinikum-magdeburg.de", 
                "last_name": "J\u00f6rg Tautenhahn, MD", 
                "phone": "+49 391 791 4300"
            }, 
            "contact_backup": {
                "email": "julia.kunze@klinikum-magdeburg.de", 
                "last_name": "Julia Kunze", 
                "phone": "+49 391 791 3115"
            }, 
            "facility": {
                "address": {
                    "city": "Magdeburg", 
                    "country": "Germany", 
                    "zip": "39130"
                }, 
                "name": "Klinikum Magdeburg"
            }, 
            "investigator": [
                {
                    "last_name": "J\u00f6rg Tautenhahn, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Arndt Hribaschek, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Katja Heerklotz", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Silver Graft All Comers Registry is to Assess the Long Term Clinical Benefit of Silver Graft in an Unselected Patient Population", 
        "other_outcome": {
            "description": "assessed through imaging (ultrasound, MRI, CT)", 
            "measure": "Freedom from perigraft fluid presence", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "joerg.tautenhahn@klinikum-magdeburg.de", 
            "last_name": "J\u00f6rg Tautenhahn, MD", 
            "phone": "+49-391 791-4300"
        }, 
        "overall_contact_backup": {
            "email": "julia.kunze@klinikum-magdeburg.de", 
            "last_name": "Julia Kunze, MD", 
            "phone": "+49-391 791-3115"
        }, 
        "overall_official": {
            "affiliation": "Klinikum Magdeburg", 
            "last_name": "J\u00f6rg Tautenhahn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "12-month patency assessed with duplex ultrasound", 
            "measure": "graft patency", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "reference": [
            {
                "PMID": "23508393", 
                "citation": "Zegelman M, Guenther G, Waliszewski M, Pukacki F, Stanisic MG, Piquet P, Passon M, Halloul Z, Tautenhahn J, Claey L, Agostinho C, Simici D, Doebrich D, Mueller C, Balzer K. Results from the International Silver Graft Registry for high-risk patients treated with a metallic-silver impregnated vascular graft. Vascular. 2013 Jun;21(3):137-47."
            }, 
            {
                "PMID": "19698298", 
                "citation": "Zegelman M, Guenther G, Florek HJ, Orend KH, Zuehlke H, Liewald F, Storck M. Results from the first in man german pilot study of the silver graft, a vascular graft impregnated with metallic silver. Vascular. 2009 Jul-Aug;17(4):190-6."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970605"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "assessed through clinical parameters, imaging (ultrasound, MRI, CT), bacterial cultures", 
            "measure": "Freedom from infection", 
            "safety_issue": "No", 
            "time_frame": "at 12 months"
        }, 
        "source": "B. Braun Melsungen AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "B. Braun Melsungen AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}